World- Page 3

Seventh patient of the trial at the second cohort SOUTH SAN FRANCISCO, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) — CERo Therapeutics Holdings, Inc. (OTCQB: CERO) (“CERo” or the “Company”), an innovative cellular

Pomeroy brings more than 35 years of thermal, energy, and technology leadership experience, including growing a business to more than $200 million in revenue MARLBOROUGH, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) —

Collaboration closes the loop between AI drug design and human biology: Chemveda designs and makes the molecules, VivoSim’s NAMkind™ 3D human liver and intestine models show which ones are safe to advance,

SAN FRANCISCO, Nov. 03, 2026 (GLOBE NEWSWIRE) — Chegg, Inc. (NYSE:CHGG), a learning and employability company, today reported financial results for the quarter ended September 30, 2026. “Over the last year our

Company reaffirms fiscal 2027 adjusted EPS and local volume guidance HOUSTON, Nov. 03, 2026 (GLOBE NEWSWIRE) — Sysco Corporation (NYSE:SYY) (“Sysco” or the “company”) today announced that Brandon Sewell, the Company’s Interim

LOUISVILLE, Ky., Nov. 03, 2026 (GLOBE NEWSWIRE) — Creative Realities, Inc. (“Creative Realities,” “CRI,” or the “Company”) (NASDAQ: CREX), a leading provider of digital signage and media solutions, announced today that it

PALO ALTO, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced today

Business will operate as Biomark Scientific, a leader in accessible, scalable and automated genomic workflows powered by proprietary microfluidics technology BOSTON, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) — Global private equity healthcare

Seasonal Initiative Builds on Established Relationship with Leading Regional Grocery Retailer BELVIDERE, NJ, Nov. 03, 2026 (GLOBE NEWSWIRE) — Edible Garden AG Incorporated (“Edible Garden” or the “Company”) (Nasdaq: EDBL, EDBLW), a

ROCKVILLE, Md., Nov. 03, 2026 (GLOBE NEWSWIRE) — Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development